Throat Cancer Clinical Trials
Treatment De-intensification Protocol for Patients with HPV+ Head and Neck Cancer
Alternate Titles:
"Combination of Low-Dose Focused Radiotherapy, Immunotherapy, and Transoral Robotic Surgery in HPV+ Head and Neck Cancer"
"Phase Ib/II Trial of Stereotactic Body Radiotherapy (SBRT) in Combination with Immunotherapy Prior to Transoral Robotic Surgery (TORS) for HPV+ Squamous Cell Carcinoma of the Head and Neck (SCCHN)"
This study is designed to evaluate a drastically reduced treatment strategy for HPV+ head and neck throat cancer. Instead of conventional options of surgery, chemotherapy, and large-field radiotherapy, this protocol uses focused radiotherapy, immunotherapy, AND robotic surgery. Focused radiotherapy is delivered to the tumor over the course of a single week in combination with state of the art IMMUNOTHERAPY. Then, Transoral robotic surgery (TORS) will be completed 6-8 weeks later. Patients will be eligible for additional 4 doses of immunotherapy as part of the trial participation. ClinicalTrials.gov Identifier: NCT03618134
To learn more about this clinical trial and more, please contact us.
Immunotherapy to Improve Outcomes in Recurrent Head and Neck Cancer
Alternate Titles:
"Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck"
"Phase Ib/II Trial of Stereotactic Body Radiotherapy (SBRT) in Combination with Immunotherapy Prior to Transoral Robotic Surgery (TORS) for HPV+ Squamous Cell Carcinoma of the Head and Neck (SCCHN)"
This is a prospective, multi-center, open label, phase II study in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) treated with IMMUNOTHERAPY following salvage surgical resection. Participating patients will receive either pembrolizumab (KEYTRUDA) administered intravenously (IV) for two doses, or a placebo infusion. Approximately three to six weeks following the first dose of pembrolizumab, patients will undergo salvage surgery. After surgery, ALL participating patients will then receive regular treatment with KEYTRUDA every 3 weeks for the first year after surgery. ClinicalTrials.gov Identifier: NCT02769520
To learn more about this clinical trial and more, please contact us.
